Stay informed about the recent drug safety alert on Mefenamic acid, a widely used painkiller in India. The Indian Pharmacopoeia Commission (IPC) highlights concerns about Mefenamic acid active ingredients of painkillers, and its potential to cause adverse reactions. Learn about the risks, and symptoms of DRESS syndrome, and how healthcare professionals and consumers can respond.
Introduction
In a recent development, the Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert regarding Mefenamic acid , a popular painkiller key ingredient in India known for its efficacy in alleviating pain, menstrual cramps, and rheumatoid arthritis.
Mefenamic Acid
Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID).This addresses both pain and spasms, offering comprehensive relief.
How it Works?
- Mefenamic Acid: As an NSAID, mefenamic acid works by inhibiting the production of prostaglandins, substances in the body that contribute to inflammation and pain. By reducing prostaglandin levels, Meftal Spas helps alleviate pain and discomfort.
Purposes of Usage
Mefenamic acid is widely prescribed for the following purposes:
- Pain Relief: It is commonly used to alleviate moderate to severe pain, making it a go-to choice for individuals dealing with conditions like migraines, dental pain, or postoperative discomfort.
- Menstrual Cramps: It is a trusted solution for relieving the intense pain associated with menstrual cramps, providing comfort to countless women during their menstrual cycles.
- Rheumatoid Arthritis: Its anti-inflammatory properties make Mefenamic acid effective in managing pain and inflammation associated with rheumatoid arthritis.
Concerns
The IPC’s drug safety alert focuses on the active ingredient mefenamic acid, and raises concerns about potential adverse reactions. Individuals relying on this may be at risk of developing eosinophilia and systemic symptoms (DRESS) syndrome.
Understanding DRESS Syndrome
DRESS syndrome, an acronym for Drug Reaction with Eosinophilia and Systemic Symptoms, is a severe and potentially life-threatening hypersensitivity reaction to certain medications. It manifests through a combination of symptoms, including a widespread rash, high fever, swelling of lymph nodes and internal organs, and an increase in eosinophils in the blood.
Key Features of DRESS Syndrome:
- Skin Rash: Typically begins with an itchy and red rash, often starting on the face and spreading to other parts of the body.
- Fever: Individuals with DRESS syndrome experience a high fever.
- Swelling: Lymph nodes and internal organs, such as the liver, lungs, and heart, may swell.
- Organ Involvement: DRESS syndrome can affect multiple organs, leading to hepatitis, pneumonitis, and myocarditis.
- Eosinophilia: An increase in eosinophils, a type of white blood cell involved in the immune response.
Preventive Measures and Alternatives
- Healthcare Professional Guidance: Individuals using Mefenamic acid are encouraged to consult with healthcare professionals for personalized guidance. Health professionals can provide insights into alternative pain management strategies and suitable substitutes.
- Pharmacovigilance Participation: By actively participating in pharmacovigilance efforts, consumers contribute to a collective understanding of medication safety. This involvement helps in creating a safer healthcare environment for everyone.
Government Advisory
The alert emphasizes the importance of healthcare professionals and consumers closely monitoring the possibility of adverse drug reactions associated with Mefenamic acid. The government advises promptly reporting any adverse reactions to the national coordination center of the Pharmacovigilance Programme of India (PvPI).
How to Report Adverse Reactions
Individuals are encouraged to submit their reports through various channels, including the IPC website (www.ipc.gov.in), the Android mobile app ADR PvPI, or by contacting the PvPI Helpline Number at 1800-180-3024.
Conclusion
As the alert sheds light on potential risks associated with Mefenamic acid, it becomes crucial for healthcare professionals and consumers to be vigilant. Stay informed, monitor for adverse reactions, and promptly report any concerns to contribute to the ongoing Pharmacovigilance Programme of India.
